Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6015138 | 0.88 | HPGD (0.54) | KMT2ANR1I2SMN1; SMN2HPGDLMNA | |
| SCHEMBL5300596 | 0.88 | HPGD (0.50) | KMT2ANR1I2SMN1; SMN2HPGDLMNA | |
| SCHEMBL5304073 | 0.87 | NR1I2 (0.59) | KMT2ANR1I2KDM4ERAB9ANPC1 | |
| SCHEMBL5305767 | 0.85 | NR1I2 (0.45) | KMT2ANR1I2KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL5300317 | 0.84 | NR1I2 (0.48) | KMT2ANR1I2SMN1; SMN2HPGDLMNA | |
| SCHEMBL5292819 | 0.84 | NR1I2 (0.48) | KMT2ANR1I2KDM4ESMN1; SMN2HPGD | |
| SCHEMBL5293985 | 0.84 | HSPD1 (0.45) | KMT2ANR1I2KDM4ESMN1; SMN2HPGD | |
| SCHEMBL5285074 | 0.84 | LMNA (0.53) | KMT2ANR1I2SMN1; SMN2HPGDLMNA | |
| SCHEMBL5410518 | 0.84 | NR1I2 (0.61) | KMT2ANR1I2SMN1; SMN2HPGDLMNA | |
| SCHEMBL5291553 | 0.83 | NR1I2 (0.60) | KMT2ANR1I2SMN1; SMN2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | KMT2A 3680/4885NR1I2 1911/4885KDM4E 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.